Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
41055698 (PubMed )
Supplement: BLOOD_BLD-2024-027009-mmc4.xlsx › Sheet_1
EZHIP boosts neuronal-like synaptic gene programs and depresses polyamine metabolism.
Hasheminasabgorji E et al.
Acta Neuropathologica Communications, 2025
41204377 (PubMed )
Supplement: 40478_2025_2141_MOESM3_ESM.xlsx › EZH2
Unravelling the role of PLK1 in tumorigenesis by revealing the mutational landscape of colorectal and lung cancer with PLK1 mutations.
Wang S et al.
Journal of Cellular and Molecular Medicine, 2024
38887977 (PubMed )
Supplement: JCMM-28-e18497-s002.xlsx › Sheet1
Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8.
Toribio-Castelló S et al.
Cancers, 2023
37568638 (PubMed )
Supplement: cancers-15-03822-s001.zip › Supplementary_tables.xlsx › Table_S2
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G et al.
Blood Advances, 2023
36375042 (PubMed )
Supplement: BLOODA_ADV-2022-008204-mmc1.pdf
Diverse monogenic subforms of human spermatogenic failure.
Nagirnaja L et al.
Nature Communications, 2022
36572685 (PubMed )
Supplement: 41467_2022_35661_MOESM3_ESM.xlsx › Supplementary_Data_1
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J et al.
Clinical Epigenetics, 2021
Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice.
Čerina D et al.
Pathology Oncology Research : Por, 2021
34646088 (PubMed )
Supplement: DataSheet2.docx
EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.
Stasik S et al.
Haematologica, 2020
Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Montes P et al.
Oncotarget, 2018
30651926 (PubMed )
Supplement: oncotarget-09-36929-s001.pdf
Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT et al.
Oncotarget, 2017
29291002 (PubMed )
Supplement: oncotarget-08-106948-s002.xls › Hoja1
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Ernst T et al.
Nature Genetics, 2010
Select a paper to view details